Symbicort® COPD (budesonide/formoterol)

Symbicort® Turbohaler® and Symbicort® pMDI are combinations of an inhaled corticosteroid and a long-acting β2-agonist 

Chronic obstructive pulmonary disease (COPD) and Symbicort®

Device choice in COPD

Symbicort offers device choice for your COPD patients with Turbohaler and pMDI*

*Symbicort pMDI is to be used in the treatment of COPD and is not approved within the EU for the treatment of asthma. Symbicort® pMDI is not to be used as a reliever medication, and consequently is not suitable for use as maintenance and reliever therapy (i.e. SMART).

**Particles in the aerodynamic size range from 1.5–5 μm are shown to be optimal, as particles <1.0 μm are very likely to be exhaled again while those >5 μm may impact on the oropharynx and be swallowed, potentially contributing to a reduction in efficacy and local oropharyngeal or systemic effects.7 Symbicort® metered dose particle size data are taken from in vitro studies.7, 8 Symbicort® metered dose mass median aerodynamic diameter (MMAD) = 2.07 μm.8